First there was a blizzard of new drug deals. Now comes the forecast for sunnier financial weather ahead.
AstraZeneca CEO Pascal Soriot arrived at JPMorgan with a message: The pharma giant ($AZN) has beefed up its late-stage pipeline and is now ready to prove it can start to grow again in the near future as it pushes through one of the industry’s most radical R&D reorganizations. As of today, AstraZeneca counts 11 drugs in late stages of development–just about double what Soriot inherited when he was named CEO a year ago–with another 27 coming up behind it. And it’s mapped out a combo strategy for immunotherapies designed to get the company in the race to gain approvals and start growing oncology revenue.
{iframe}http://www.fiercebiotech.com/story/astrazenecas-soriot-faces-against-skeptics-preaches-late-stage-rd-revival/2014-01-14{/iframe}